170 related articles for article (PubMed ID: 37387721)
1. Treating Advanced Hepatocellular Carcinoma with Sorafenib: A 10-Year Single Center Experience.
Presa Ramos J; Tavares S; Barreira A; Pimenta JL; Carvalho S; Carrola P; Pinho I
GE Port J Gastroenterol; 2023 Jun; 30(3):213-220. PubMed ID: 37387721
[TBL] [Abstract][Full Text] [Related]
2. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Jun; 33(3):729-39. PubMed ID: 25861764
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
6. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma.
Kim B; Kim SS; Cho SW; Cheong JY; Huh J; Kim JK; Lee JH; Ahn HR; Cho HJ
Eur Radiol; 2021 Apr; 31(4):2507-2517. PubMed ID: 33033862
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma.
DA Fonseca LG; Barroso-Sousa R; Bento AD; Blanco BP; Valente GL; Pfiffer TE; Hoff PM; Sabbaga J
Mol Clin Oncol; 2015 Jul; 3(4):793-796. PubMed ID: 26171182
[TBL] [Abstract][Full Text] [Related]
9. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
Huang CC; Chen HY; Chang RH; Liao PA; Lien HH; Hung CS; Yang SS; Hu JT
Drug Des Devel Ther; 2019; 13():397-404. PubMed ID: 30774305
[TBL] [Abstract][Full Text] [Related]
10. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.
Hu K; Yuan J; Tang B; Zhang F; Lu S; Chen R; Zhang L; Ren Z; Yin X
Ann Transl Med; 2021 Feb; 9(3):237. PubMed ID: 33708864
[TBL] [Abstract][Full Text] [Related]
11. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
Kudo M; Galle PR; Brandi G; Kang YK; Yen CJ; Finn RS; Llovet JM; Assenat E; Merle P; Chan SL; Palmer DH; Ikeda M; Yamashita T; Vogel A; Huang YH; Abada PB; Yoshikawa R; Shinozaki K; Wang C; Widau RC; Zhu AX
JHEP Rep; 2021 Apr; 3(2):100215. PubMed ID: 33392490
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
13. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Blanc JF; Khemissa F; Bronowicki JP; Monterymard C; Perarnau JM; Bourgeois V; Obled S; Abdelghani MB; Mabile-Archambeaud I; Faroux R; Seitz JF; Locher C; Senellart H; Villing AL; Audemar F; Costentin C; Deplanque G; Manfredi S; Edeline J;
Hepatol Int; 2021 Feb; 15(1):93-104. PubMed ID: 33420951
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK; Rimassa L; Cheng AL; Kaseb A; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Banerjee K; Hazra S; Fawcett J; Yau T
Lancet Oncol; 2022 Aug; 23(8):995-1008. PubMed ID: 35798016
[TBL] [Abstract][Full Text] [Related]
16. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
[TBL] [Abstract][Full Text] [Related]
17. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.
Patidar Y; Chandel K; Condati NK; Srinivasan SV; Mukund A; Sarin SK
J Clin Exp Hepatol; 2022; 12(3):745-754. PubMed ID: 35677519
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.
Nakano M; Niizeki T; Nagamatsu H; Tanaka M; Kuromatsu R; Satani M; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T;
Mol Clin Oncol; 2017 Dec; 7(6):1013-1020. PubMed ID: 29285366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]